Sign in

    Caroline Corner

    Managing Director and Senior Research Analyst at Cantor Fitzgerald

    Caroline Corner is a Managing Director and Senior Research Analyst at Cantor Fitzgerald, specializing in equity research of medical technology companies within the healthcare sector. She has covered a range of small- and mid-cap firms—including Aerie Pharmaceuticals (AERI), Cerus Corporation (CERS), and Alimera Sciences (ALIM)—and her performance metrics on TipRanks show a 40% success rate with an average return of -1.90%, though her top calls have achieved returns over 320%. Corner began her finance career after engineering roles at Baxter and Eli Lilly, holding senior analyst positions at Wells Fargo Securities, Pacific Growth Equities, and MLV & Co. before joining Cantor Fitzgerald as Managing Director in 2014. She holds a PhD in Biological Engineering from Cornell University, a BS from Virginia Tech, and has been active in numerous IPOs and capital raises for life sciences companies.

    Caroline Corner's questions to STEM (STEM) leadership

    Caroline Corner's questions to STEM (STEM) leadership • Q2 2015

    Question

    Caroline Corner of Cantor Fitzgerald asked if the new analysis of the five Phase I/II AMD patients who would qualify for the Radiant study was helping with site enrollment. She also questioned the day-to-day impact on the company's business plan following the dismissal of the patent infringement case against Neuralstem.

    Answer

    President and COO Dr. Ian Massey responded that while there was already enthusiasm from sites, the new data is recent and will be shared with investigators, which he believes will be reassuring for both them and for patients. CEO Martin McGlynn reiterated that the patent case decision has no impact on the company's ability to execute its business plan, as it was about another party's ability to operate, not their own.

    Ask Fintool Equity Research AI